Recent Advances and Future Perspectives in Radiolabeled Antibody Fragments for Breast Cancer Molecular Imaging
-
Reza Gerami
,
Mana Altafi
,
Zahra Shahpar
,
Ensieh Izadpanah
,
Siamak Soltani
,
Omid Naderloo
,
Ali Tarighatnia
Abstract
Breast Cancer (BC) is the leading cause of cancer-related deaths in women and the most common cancer worldwide. It is classified based on its anatomical origin, the presence of Human Epidermal Growth Factor Receptor 2 (HER-2), and the presence of Estrogen Receptor (ER) and/or Progesterone Receptor (PR). Around 20% of breast cancers are HER-2 positive. While biopsy-based diagnoses are valuable in clinical settings, they have limitations in terms of sampling and interpretation. However, laboratory tests such as Immunohistochemistry (IHC) or Fluorescence In Situ Hybridization (FISH) are also limited, including being time-consuming, expensive, and requiring specialized equipment. Ongoing research and technological advancements aim to address the challenges associated with biopsy-based diagnoses and laboratory tests to develop more accurate and efficient methods for assessing HER-2 status. To this end, various radioactively labeled proteins and small compounds, such as single-chain variable Fragments (scFv), F(ab')2, affibody, and nanobody, have been developed to target HER-2 using molecular array techniques. These smaller targeted compounds offer improved image quality, shorter circulating half-life, and reduced immunogenicity compared to their larger counterparts. This is due to their better biodistribution, clearance, and stability. This study investigates the current understanding and ongoing efforts in utilizing antibody fragments for molecular imaging. The specific objectives were to evaluate the advantages of antibody fragments over full-length antibodies regarding biodistribution, clearance, and stability. Additionally, this study aims to assess the current knowledge and ongoing research in utilizing antibody fragments for molecular imaging.
1- B. Smolarz, A. Z. Nowak, and H. Romanowicz, "Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)." (in eng), Cancers (Basel), Vol. 14 (No. 10), May 23 (2022).
2- M. Torabi, A. Aghanejad, P. Savadi, A. Barzegari, Y. Omidi, and J. Barar, "Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles." (in English), Molecules, Article Vol. 28 (No. 1), (2023), Art no. 411.
3- P. Siminzar, M. R. Tohidkia, E. Eppard, N. Vahidfar, A. Tarighatnia, and A. Aghanejad, "Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment." (in English), Molecular Imaging and Biology, Review Vol. 25 (No. 3), pp. 464-82, (2023).
4- J. Kadkhoda, A. Tarighatnia, M. R. Tohidkia, N. D. Nader, and A. Aghanejad, "Photothermal therapy-mediated autophagy in breast cancer treatment: Progress and trends." (in English), Life Sciences, Review Vol. 298(2022), Art no. 120499.
5- Ganesh N Sharma, Rahul Dave, Jyotsana Sanadya, Piush Sharma, and KK22247839 Sharma, "Various types and management of breast cancer: an overview." Journal of advanced pharmaceutical technology & research, Vol. 1 (No. 2), p. 109, (2010).
6- László Tabár et al., "Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB." European Journal of Radiology, Vol. 152p. 110323, (2022).
7- J. Kadkhoda, A. Tarighatnia, N. D. Nader, and A. Aghanejad, "Targeting mitochondria in cancer therapy: Insight into photodynamic and photothermal therapies." (in English), Life Sciences, Review Vol. 307(2022), Art no. 120898.
8- A. Aghanejad et al., "Synthesis and evaluation of [67Ga]-AMD3100: A novel imaging agent for targeting the chemokine receptor CXCR4." (in English), Scientia Pharmaceutica, Article Vol. 82 (No. 1), pp. 29-42, (2014).
9- A. Ajoolabady et al., "Enzyme-based autophagy in anti-neoplastic management: From molecular mechanisms to clinical therapeutics." (in English), Biochimica et Biophysica Acta - Reviews on Cancer, Review Vol. 1874 (No. 1), (2020), Art no. 188366.
10- Iveta Kolářová et al., "Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients." Biomedical Papers, volume 165, issue: 1, (2021).
11- Gillian C Bethune et al., "Impact of the 2013 A merican S ociety of C linical O ncology/C ollege of A merican P athologists guideline recommendations for human epidermal growth factor receptor 2 (HER 2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’for HER 2 gene amplification by fluorescence in‐situ hybridization." Histopathology, Vol. 67 (No. 6), pp. 880-87, (2015).
12- N. Hashemzadeh et al., "Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines." (in English), Life Sciences, Review Vol. 271(2021), Art no. 119110.
13- J. Kadkhoda, A. Aghanejad, B. Safari, J. Barar, S. H. Rasta, and S. Davaran, "Aptamer-conjugated gold nanoparticles for targeted paclitaxel delivery and photothermal therapy in breast cancer." (in English), Journal of Drug Delivery Science and Technology, Article Vol. 67(2022), Art no. 102954.
14- B. Foroughi-Nia, J. Barar, M. Y. Memar, A. Aghanejad, and S. Davaran, "Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors." (in English), Life Sciences, Review Vol. 278(2021), Art no. 119642.
15- Ali Tarighatnia, Behrouz Foroughi-Nia, Nader D. Nader, and Ayuob Aghanejad, "Recent trends and advances in nanosystems with tyrosine kinase inhibitors for image-guided cancer treatments." Journal of Drug Delivery Science and Technology, Vol. 88p. 104938, 2023/10/01/ (2023).
16- Xiaolu Sun, Kuai Liu, Shuli Lu, Weina He, and Zixiu Du, "Targeted therapy and immunotherapy for heterogeneous breast cancer." Cancers, Vol. 14 (No. 21), p. 5456, (2022).
17- Steven J Potts et al., "Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue." Laboratory investigation, Vol. 92 (No. 9), pp. 1342-57, (2012).
18- Leopoldo Sitia et al., "HER-2-targeted nanoparticles for breast cancer diagnosis and treatment." Cancers, Vol. 14 (No. 10), p. 2424, (2022).
19- Khalid Jazieh, Ruth Bell, Nayan Agarwal, and Jame Abraham, "Novel targeted therapies for metastatic breast cancer." Annals of Translational Medicine, Vol. 8 (No. 14), (2020).
20- Kuo Zhang, Haiyan Xu, and Kai Li, "Molecular Imaging for Early-Stage Disease Diagnosis." in Visualized Medicine: Emerging Techniques and Developing Frontiers: Springer, (2023), pp. 39-58.
21- Zhongquan Cheng et al., "Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50 (No. 4), pp. 1111-33, (2023).
22- Ali Tarighatnia, Gurkaran Johal, Ayuob Aghanejad, Hossein Ghadiri, and Nader D Nader, "Tips and tricks in molecular imaging: a practical approach." Frontiers in Biomedical Technologies, Vol. 8 (No. 3), pp. 226-35, (2021).
23- Saima Muzahir, Gary A Ulaner, and David M Schuster, "Evaluation of treatment response in patients with breast cancer." PET clinics, (2023).
24- Tapan Behl et al., "Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer." International Journal of Biological Macromolecules, p. 126595, (2023).
25- Mohammad Sameer Khan et al., "Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer." International journal of pharmaceutics, p. 123276, (2023).
26- Yutian Feng, Rebecca Meshaw, Xiao-Guang Zhao, Stephen Jannetti, Ganesan Vaidyanathan, and Michael R Zalutsky, "Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 124-30, (2023).
27- Palmira Alessia Cavallaro et al., "Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics." Nanomaterials, Vol. 13 (No. 17), p. 2476, (2023).
28- Runlong Lin, Huiyun Lv, Jing Yu, Aijuan Tian, and Chen Song, "FDG PET/CT, Precise Positioning of the Criminal Focus in the Osteogenic Region of Breast Cancer Bone Metastases after Therapy." (2023).
29- M. Dolatkhah et al., "Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer." (in English), Colloids and Surfaces B: Biointerfaces, Review Vol. 193(2020), Art no. 111104.
30- Sylvia Annabel Dass et al., "Triple negative breast cancer: A review of present and future diagnostic modalities." Medicina, Vol. 57 (No. 1), p. 62, (2021).
31- A. Nourizad, S. Golmohammadi, A. Aghanejad, and M. R. Tohidkia, "Recent trends in aptamer-based nanobiosensors for detection of vascular endothelial growth factors (VEGFs) biomarker: A review." (in English), Environmental Research, Review Vol. 236(2023), Art no. 116726.
32- Roman Beňačka, Daniela Szabóová, Zuzana Guľašová, Zdenka Hertelyová, and Jozef Radoňák, "Classic and new markers in diagnostics and classification of breast cancer." Cancers, Vol. 14 (No. 21), p. 5444, (2022).
33- Stuart J Schnitt, Edi Brogi, Yunn-Yi Chen, Tari A King, and Sunil R Lakhani, "American registry of pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications." Annals of diagnostic pathology, Vol. 45p. 151481, (2020).
34- Sheela Bukya, Aparna Suryadevara, Sanjeeva Kumari Chinta, and B Triveni, "Evaluation of Rare Types of Breast Cancer among Indian Patients–a Retrospective Study from a Regional Cancer Center." Indian Journal of Surgical Oncology, Vol. 12pp. 286-89, (2021).
35- N. Hashemzadeh et al., "Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells." (in English), Nanomedicine, Article Vol. 16 (No. 24), pp. 2137-54, (2021).
36- A. Aghanejad et al., "A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors." (in English), International Journal of Biological Macromolecules, Review Vol. 207pp. 592-610, (2022).
37- Typically Benign Calcifications, "Mammographic Analysis of Breast Calcifications." Breast Imaging, E-Book: The Core Requisites, p. 36, (2022).
38- Luigi Rossi et al., "Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy." Cancer Chemotherapy and Pharmacology, Vol. 85pp. 105-11, (2020).
39- A. Aghanejad, A. R. Jalilian, S. Maus, H. Yousefnia, P. Geramifar, and D. Beiki, "Optimized production and quality control of 68Ga-DOTATATE." (in English), Iranian Journal of Nuclear Medicine, Article Vol. 24 (No. 1), pp. 29-36, (2016).
40- A. Aghanejad, A. R. Jalilian, Y. Fazaeli, D. Beiki, B. Fateh, and A. Khalaj, "Radiosynthesis and biodistribution studies of [62Zn/ 62Cu]-plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging." (in English), Journal of Radioanalytical and Nuclear Chemistry, Article Vol. 299 (No. 3), pp. 1635-44, (2014).
41- A. Tarighatnia et al., "Mucin-16 targeted mesoporous nano-system for evaluation of cervical cancerviadual-modal computed tomography and ultrasonography." (in English), New Journal of Chemistry, Article Vol. 45 (No. 40), pp. 18871-80, (2021).
42- M. Saberian, H. Hamzeiy, A. Aghanejad, and D. Asgari, "Aptamer-based nanosensors: Juglone as an attached-redox molecule for detection of small molecules." (in English), BioImpacts, Article Vol. 1 (No. 1), pp. 31-36, (2011).
43- S. Mohaghegh, A. Tarighatnia, Y. Omidi, J. Barar, A. Aghanejad, and K. Adibkia, "Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer." (in English), Journal of Microencapsulation, Article Vol. 39 (No. 4), pp. 394-408, (2022).
44- A. Tarighatnia et al., "Engineering and quantification of bismuth nanoparticles as targeted contrast agent for computed tomography imaging in cellular and animal models." (in English), Journal of Drug Delivery Science and Technology, Article Vol. 66(2021), Art no. 102895.
45- F. Vahidian et al., "siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468)." (in English), Molecular Biology Reports, Article Vol. 47 (No. 12), pp. 9541-51, (2020).
46- A. Mirzaei et al., "Preparation and Evaluation of 68Ga-ECC as a PET Renal Imaging Agent." (in English), Nuclear Medicine and Molecular Imaging, Article Vol. 49 (No. 3), pp. 208-16, (2015).
47- S. Rezaei, E. Gharapapagh, S. Dabiri, P. Heidari, and A. Aghanejad, "Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges." (in English), Life Sciences, Review Vol. 329(2023), Art no. 121970.
48- K. Kheyrolahzadeh, M. R. Tohidkia, A. Tarighatnia, P. Shahabi, N. D. Nader, and A. Aghanejad, "Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors." (in English), Life Sciences, Review Vol. 328(2023), Art no. 121917.
49- N. Vahidfar, A. Aghanejad, H. Ahmadzadehfar, S. Farzanehfar, and E. Eppard, "Theranostic advances in breast cancer in nuclear medicine." (in English), International Journal of Molecular Sciences, Review Vol. 22 (No. 9), (2021), Art no. 4597.
50- J. Kadkhoda, M. Akrami-Hasan-Kohal, M. R. Tohidkia, S. Khaledi, S. Davaran, and A. Aghanejad, "Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends." (in English), International Journal of Biological Macromolecules, Review Vol. 185pp. 664-78, (2021).
51- Javad Biabani Ardakani et al., "Molecular imaging of HER2 expression in breast cancer patients using the [99mTc] Tc-labeled small peptide." Clinical Breast Cancer, Vol. 23 (No. 2), pp. 219-30, (2023).
52- Rong Zhou et al., "18F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 131-36, (2023).
53- Jaehoon Shin et al., "Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 137-44, (2023).
54- Nasim Vahidfar, Ayuob Aghanejad, Hojjat Ahmadzadehfar, Saeed Farzanehfar, and Elisabeth Eppard, "Theranostic Advances in Breast Cancer in Nuclear Medicine." International Journal of Molecular Sciences. Vol. 22 (No. 9). DOI: 10.3390/ijms22094597
55- D. Asgari, A. Aghanejad, and J. S. Mojarrad, "An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate." (in English), Bulletin of the Korean Chemical Society, Article Vol. 32 (No. 3), pp. 909-14, (2011).
56- L. Barghi, A. Aghanejad, H. Valizadeh, J. Barar, and D. Asgari, "Modified Synthesis of Erlotinib Hydrochloride." (in English), Advanced Pharmaceutical Bulletin, Article Vol. 2 (No. 1), pp. 119-22, (2012).
57- Catherine Van Poznak et al., "Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline." Journal of clinical oncology, Vol. 33 (No. 24), p. 2695, (2015).
58- SM Kurian et al., "Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling." American Journal of Transplantation, Vol. 14 (No. 5), pp. 1164-72, (2014).
59- Emran Askari, Sara Harsini, Nasim Vahidfar, Ghasemali Divband, and Ramin Sadeghi, "177Lu-EDTMP for metastatic bone pain palliation: A systematic review and meta-analysis." Cancer biotherapy & radiopharmaceuticals, Vol. 36 (No. 5), pp. 383-90, (2021).
60- Naoki Niikura et al., "Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry." Annals of oncology, Vol. 27 (No. 3), pp. 480-87, (2016).
61- Naoki Niikura et al., "Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors." Journal of clinical oncology, Vol. 30 (No. 6), p. 593, (2012).
62- Thomas Decker et al., "Clonal evolution in patients with hormone receptor positive, HER-2 negative breast cancer treated with chemotherapy or CDK4/6 inhibitors." Oncology Research and Treatment, Vol. 45 (No. 5), pp. 248-53, (2022).
63- Ibiayi Dagogo-Jack and Alice T Shaw, "Tumour heterogeneity and resistance to cancer therapies." Nature reviews Clinical oncology, Vol. 15 (No. 2), pp. 81-94, (2018).
64- N. Vahidfar et al., "Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in beast carcinoma xenografts." (in English), Radiochimica Acta, Article Vol. 102 (No. 7), pp. 659-68, (2014).
65- P. N. Nabi, N. Vahidfar, M. R. Tohidkia, A. A. Hamidi, Y. Omidi, and A. Aghanejad, "Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer." (in English), International Journal of Biological Macromolecules, Article Vol. 174pp. 185-97, (2021).
66- A. Tarighatnia, M. R. Fouladi, N. D. Nader, A. Aghanejad, and H. Ghadiri, "Recent trends of contrast agents in ultrasound imaging: a review of the classifications and applications." (in English), Materials Advances, Review (2022).
67- Tjeerd S Aukema et al., "The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques." European Journal of Surgical Oncology (EJSO), Vol. 36 (No. 4), pp. 387-92, (2010).
68- Oreste Bagni, Luca Filippi, and Orazio Schillaci, "The role of 18F-FDG positron emission tomography in the follow-up of liver tumors treated with 90Yttrium radioembolization." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 5 (No. 3), p. 220, (2015).
69- Maria Rinzivillo et al., "Clinical usefulness of 18F‐fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero‐pancreatic neuroendocrine neoplasms." The Oncologist, Vol. 23 (No. 2), pp. 186-92, (2018).
70- Jens Sörensen et al., "Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT." Theranostics, Vol. 6 (No. 2), p. 262, (2016).
71- Irina Velikyan et al., "Diagnostic HER2-binding radiopharmaceutical,[68Ga] Ga-ABY-025, for routine clinical use in breast cancer patients." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 9 (No. 1), p. 12, (2019).
72- Gustavo A Viani, Sergio L Afonso, Eduardo J Stefano, Ligia I De Fendi, and Francisco V Soares, "Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials." BMC cancer, Vol. 7 (No. 1), pp. 1-11, (2007).
73- Eva Karlsson et al., "Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events." European journal of cancer, Vol. 50 (No. 3), pp. 517-24, (2014).
74- J Zidan, I Dashkovsky, C Stayerman, W Basher, C Cozacov, and A Hadary, "Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease." British journal of cancer, Vol. 93 (No. 5), pp. 552-56, (2005).
75- Frederike Bensch et al., "89 Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45pp. 2300-06, (2018).
76- Kenji Tamura et al., "64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer." Journal of Nuclear Medicine, Vol. 54 (No. 11), pp. 1869-75, (2013).
77- Seyed Pezhman Shirmardi et al., "Preparation and biodistribution study of a 99mTc-labeled toxic fraction of Iranian mesobuthus eupeus scorpion venom." (2010).
78- Paolo Rainone et al., "Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer." International journal of nanomedicine, pp. 3447-61, (2017).
79- Jens Sörensen et al., "First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule." Journal of Nuclear Medicine, Vol. 55 (No. 5), pp. 730-35, (2014).
80- Frank Alexis, Eric Pridgen, Linda K Molnar, and Omid C Farokhzad, "Factors affecting the clearance and biodistribution of polymeric nanoparticles." Molecular pharmaceutics, Vol. 5 (No. 4), pp. 505-15, (2008).
81- S. Khajeh, M. R. Tohidkia, A. Aghanejad, T. Mehdipour, F. Fathi, and Y. Omidi, "Phage display selection of fully human antibody fragments to inhibit growth-promoting effects of glycine-extended gastrin 17 on human colorectal cancer cells." (in English), Artificial Cells, Nanomedicine and Biotechnology, Article Vol. 46 (No. sup2), pp. 1082-90, (2018).
82- Hui Ma and Richard O’Kennedy, "The structure of natural and recombinant antibodies." Peptide Antibodies: Methods and Protocols, pp. 7-11, (2015).
83- Robyn L Stanfield and Ian A Wilson, "Antibody structure." Antibodies for Infectious Diseases, pp. 49-62, (2015).
84- Hennie R Hoogenboom, Andrew D Griffiths, Kevin S Johnson, David J Chiswell, Peter Hudson, and Greg Winter, "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains." Nucleic acids research, Vol. 19 (No. 15), pp. 4133-37, (1991).
85- Mark L Chiu, Dennis R Goulet, Alexey Teplyakov, and Gary L Gilliland, "Antibody structure and function: the basis for engineering therapeutics." Antibodies, Vol. 8 (No. 4), p. 55, (2019).
86- Karen Lam, Conrad Chan, and Raymond M Reilly, "Development and preclinical studies of 64Cu-NOTA-pertuzumab F (ab′) 2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT." in MAbs, (2017), Vol. 9 (No. 1): Taylor & Francis, pp. 154-64.
87- Peter M Smith-Jones, David B Solit, Timothy Akhurst, Farzana Afroze, Neal Rosen, and Steven M Larson, "Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors." Nature biotechnology, Vol. 22 (No. 6), pp. 701-06, (2004).
88- Ying Tang et al., "Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments." Nuclear medicine and biology, Vol. 32 (No. 1), pp. 51-58, (2005).
89- Ying Tang, Deborah Scollard, Paul Chen, Judy Wang, Claire Holloway, and Raymond M Reilly, "Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments." Nuclear medicine communications, Vol. 26 (No. 5), pp. 427-32, (2005).
90- Thijs H Oude Munnink et al., "Lapatinib and 17AAG reduce 89Zr-trastuzumab-F (ab′) 2 uptake in SKBR3 tumor xenografts." Molecular pharmaceutics, Vol. 9 (No. 11), pp. 2995-3002, (2012).
91- Claudia T Mendler, Torben Gehring, Hans-Jürgen Wester, Markus Schwaiger, and Arne Skerra, "89Zr-labeled versus 124I-labeled αHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo." Journal of Nuclear Medicine, Vol. 56 (No. 7), pp. 1112-18, (2015).
92- Volkan Beylergil et al., "Pilot study of 68Ga-DOTA-F (ab′) 2-trastuzumab in patients with breast cancer." Nuclear medicine communications, Vol. 34 (No. 12), p. 1157, (2013).
93- Gregory P Adams et al., "Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv." Cancer Research, Vol. 53 (No. 17), pp. 4026-34, (1993).
94- GP Adams et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu." British journal of cancer, Vol. 77 (No. 9), pp. 1405-12, (1998).
95- Irina V Balalaeva, Tatiana A Zdobnova, Irina V Krutova, Anna A Brilkina, Ekaterina N Lebedenko, and Sergey M Deyev, "Passive and active targeting of quantum dots for whole‐body fluorescence imaging of breast cancer xenografts." Journal of Biophotonics, Vol. 5 (No. 11‐12), pp. 860-67, (2012).
96- Mikaela Friedman and Stefan Ståhl, "Engineered affinity proteins for tumour‐targeting applications." Biotechnology and applied biochemistry, Vol. 53 (No. 1), pp. 1-29, (2009).
97- Nasim Vahidfar, Saeed Farzanefar, Hojjat Ahmadzadehfar, Eóin N Molloy, and Elisabeth Eppard, "A review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies." Cancers, Vol. 14 (No. 7), p. 1779, (2022).
98- Mohamed Altai et al., "Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA." Nuclear medicine and biology, Vol. 39 (No. 4), pp. 518-29, (2012).
99- Torun Engfeldt et al., "Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99m Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34pp. 722-33, (2007).
100- Anna Orlova et al., "Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors." Cancer Research, Vol. 67 (No. 5), pp. 2178-86, (2007).
101- Vladimir Tolmachev et al., "111In-benzyl-DTPA–ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors." Journal of Nuclear Medicine, Vol. 47 (No. 5), pp. 846-53, (2006).
102- Richard P Baum et al., "Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules." Journal of Nuclear Medicine, Vol. 51 (No. 6), pp. 892-97, (2010).
103- Mattias Sandström et al., "Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients." Journal of Nuclear Medicine, Vol. 57 (No. 6), pp. 867-71, (2016).
104- Jiong Cai et al., "Non-invasive monitoring of HER2 expression in breast cancer patients with 99mTc-Affibody SPECT/CT." Iranian Journal of Radiology, Vol. 17 (No. 1), (2020).
105- Shushan Ge et al., "radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides." Molecules, Vol. 26 (No. 21), p. 6482, (2021).
106- Ruisi Fu, Laurence Carroll, Gokhan Yahioglu, Eric O Aboagye, and Philip W Miller, "Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications." ChemMedChem, Vol. 13 (No. 23), pp. 2466-78, (2018).
107- Vladimir Tolmachev and Anna Orlova, "Affibody molecules as targeting vectors for PET imaging." Cancers, Vol. 12 (No. 3), p. 651, (2020).
108- Joachim Feldwisch and Vladimir Tolmachev, "Engineering of affibody molecules for therapy and diagnostics." Therapeutic Proteins: Methods and Protocols, pp. 103-26, (2012).
109- Andrew S Greenberg, David Avila, Marianne Hughes, Austin Hughes, E Churchill McKinney, and Martin F Flajnik, "A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks." nature, Vol. 374 (No. 6518), pp. 168-73, (1995).
110- CTSG Hamers-Casterman et al., "Naturally occurring antibodies devoid of light chains." nature, Vol. 363 (No. 6428), pp. 446-48, (1993).
111- Philipp Holliger and Peter J Hudson, "Engineered antibody fragments and the rise of single domains." Nature biotechnology, Vol. 23 (No. 9), pp. 1126-36, (2005).
112- Thomas Hermans, Frédéric Nguyen, Maria Klepikova, Alain Dassargues, and Jef Caers, "Uncertainty quantification of medium‐term heat storage from short‐term geophysical experiments using Bayesian evidential learning." Water Resources Research, Vol. 54 (No. 4), pp. 2931-48, (2018).
113- Padmapriyadarsini Chandrasekaran, Natarajan Saravanan, Ramalingam Bethunaickan, and Srikanth Tripathy, "Malnutrition: modulator of immune responses in tuberculosis." Frontiers in immunology, Vol. 8p. 1316, (2017).
114- Catarina Xavier et al., "18F-nanobody for PET imaging of HER2 overexpressing tumors." Nuclear medicine and biology, Vol. 43 (No. 4), pp. 247-52, (2016).
115- Marleen Keyaerts et al., "Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma." Journal of Nuclear Medicine, Vol. 57 (No. 1), pp. 27-33, (2016).
116- Marleen Keyaerts et al., "Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients." Annals of oncology, Vol. 30pp. iii25-iii26, (2019).
117- Betül Altunay et al., "99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50 (No. 4), pp. 1005-13, (2023).
118- Renske Altena et al., "Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications." EJNMMI research, Vol. 13 (No. 1), p. 43, (2023).
119- Tessa De Pauw et al., "Current status and future expectations of nanobodies in oncology trials." Expert Opinion on Investigational Drugs, pp. 1-17, (2023).
2- M. Torabi, A. Aghanejad, P. Savadi, A. Barzegari, Y. Omidi, and J. Barar, "Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles." (in English), Molecules, Article Vol. 28 (No. 1), (2023), Art no. 411.
3- P. Siminzar, M. R. Tohidkia, E. Eppard, N. Vahidfar, A. Tarighatnia, and A. Aghanejad, "Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment." (in English), Molecular Imaging and Biology, Review Vol. 25 (No. 3), pp. 464-82, (2023).
4- J. Kadkhoda, A. Tarighatnia, M. R. Tohidkia, N. D. Nader, and A. Aghanejad, "Photothermal therapy-mediated autophagy in breast cancer treatment: Progress and trends." (in English), Life Sciences, Review Vol. 298(2022), Art no. 120499.
5- Ganesh N Sharma, Rahul Dave, Jyotsana Sanadya, Piush Sharma, and KK22247839 Sharma, "Various types and management of breast cancer: an overview." Journal of advanced pharmaceutical technology & research, Vol. 1 (No. 2), p. 109, (2010).
6- László Tabár et al., "Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB." European Journal of Radiology, Vol. 152p. 110323, (2022).
7- J. Kadkhoda, A. Tarighatnia, N. D. Nader, and A. Aghanejad, "Targeting mitochondria in cancer therapy: Insight into photodynamic and photothermal therapies." (in English), Life Sciences, Review Vol. 307(2022), Art no. 120898.
8- A. Aghanejad et al., "Synthesis and evaluation of [67Ga]-AMD3100: A novel imaging agent for targeting the chemokine receptor CXCR4." (in English), Scientia Pharmaceutica, Article Vol. 82 (No. 1), pp. 29-42, (2014).
9- A. Ajoolabady et al., "Enzyme-based autophagy in anti-neoplastic management: From molecular mechanisms to clinical therapeutics." (in English), Biochimica et Biophysica Acta - Reviews on Cancer, Review Vol. 1874 (No. 1), (2020), Art no. 188366.
10- Iveta Kolářová et al., "Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients." Biomedical Papers, volume 165, issue: 1, (2021).
11- Gillian C Bethune et al., "Impact of the 2013 A merican S ociety of C linical O ncology/C ollege of A merican P athologists guideline recommendations for human epidermal growth factor receptor 2 (HER 2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’for HER 2 gene amplification by fluorescence in‐situ hybridization." Histopathology, Vol. 67 (No. 6), pp. 880-87, (2015).
12- N. Hashemzadeh et al., "Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines." (in English), Life Sciences, Review Vol. 271(2021), Art no. 119110.
13- J. Kadkhoda, A. Aghanejad, B. Safari, J. Barar, S. H. Rasta, and S. Davaran, "Aptamer-conjugated gold nanoparticles for targeted paclitaxel delivery and photothermal therapy in breast cancer." (in English), Journal of Drug Delivery Science and Technology, Article Vol. 67(2022), Art no. 102954.
14- B. Foroughi-Nia, J. Barar, M. Y. Memar, A. Aghanejad, and S. Davaran, "Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors." (in English), Life Sciences, Review Vol. 278(2021), Art no. 119642.
15- Ali Tarighatnia, Behrouz Foroughi-Nia, Nader D. Nader, and Ayuob Aghanejad, "Recent trends and advances in nanosystems with tyrosine kinase inhibitors for image-guided cancer treatments." Journal of Drug Delivery Science and Technology, Vol. 88p. 104938, 2023/10/01/ (2023).
16- Xiaolu Sun, Kuai Liu, Shuli Lu, Weina He, and Zixiu Du, "Targeted therapy and immunotherapy for heterogeneous breast cancer." Cancers, Vol. 14 (No. 21), p. 5456, (2022).
17- Steven J Potts et al., "Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue." Laboratory investigation, Vol. 92 (No. 9), pp. 1342-57, (2012).
18- Leopoldo Sitia et al., "HER-2-targeted nanoparticles for breast cancer diagnosis and treatment." Cancers, Vol. 14 (No. 10), p. 2424, (2022).
19- Khalid Jazieh, Ruth Bell, Nayan Agarwal, and Jame Abraham, "Novel targeted therapies for metastatic breast cancer." Annals of Translational Medicine, Vol. 8 (No. 14), (2020).
20- Kuo Zhang, Haiyan Xu, and Kai Li, "Molecular Imaging for Early-Stage Disease Diagnosis." in Visualized Medicine: Emerging Techniques and Developing Frontiers: Springer, (2023), pp. 39-58.
21- Zhongquan Cheng et al., "Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50 (No. 4), pp. 1111-33, (2023).
22- Ali Tarighatnia, Gurkaran Johal, Ayuob Aghanejad, Hossein Ghadiri, and Nader D Nader, "Tips and tricks in molecular imaging: a practical approach." Frontiers in Biomedical Technologies, Vol. 8 (No. 3), pp. 226-35, (2021).
23- Saima Muzahir, Gary A Ulaner, and David M Schuster, "Evaluation of treatment response in patients with breast cancer." PET clinics, (2023).
24- Tapan Behl et al., "Understanding the mechanistic pathways and clinical aspects associated with protein and gene based biomarkers in breast cancer." International Journal of Biological Macromolecules, p. 126595, (2023).
25- Mohammad Sameer Khan et al., "Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer." International journal of pharmaceutics, p. 123276, (2023).
26- Yutian Feng, Rebecca Meshaw, Xiao-Guang Zhao, Stephen Jannetti, Ganesan Vaidyanathan, and Michael R Zalutsky, "Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 124-30, (2023).
27- Palmira Alessia Cavallaro et al., "Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics." Nanomaterials, Vol. 13 (No. 17), p. 2476, (2023).
28- Runlong Lin, Huiyun Lv, Jing Yu, Aijuan Tian, and Chen Song, "FDG PET/CT, Precise Positioning of the Criminal Focus in the Osteogenic Region of Breast Cancer Bone Metastases after Therapy." (2023).
29- M. Dolatkhah et al., "Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer." (in English), Colloids and Surfaces B: Biointerfaces, Review Vol. 193(2020), Art no. 111104.
30- Sylvia Annabel Dass et al., "Triple negative breast cancer: A review of present and future diagnostic modalities." Medicina, Vol. 57 (No. 1), p. 62, (2021).
31- A. Nourizad, S. Golmohammadi, A. Aghanejad, and M. R. Tohidkia, "Recent trends in aptamer-based nanobiosensors for detection of vascular endothelial growth factors (VEGFs) biomarker: A review." (in English), Environmental Research, Review Vol. 236(2023), Art no. 116726.
32- Roman Beňačka, Daniela Szabóová, Zuzana Guľašová, Zdenka Hertelyová, and Jozef Radoňák, "Classic and new markers in diagnostics and classification of breast cancer." Cancers, Vol. 14 (No. 21), p. 5444, (2022).
33- Stuart J Schnitt, Edi Brogi, Yunn-Yi Chen, Tari A King, and Sunil R Lakhani, "American registry of pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications." Annals of diagnostic pathology, Vol. 45p. 151481, (2020).
34- Sheela Bukya, Aparna Suryadevara, Sanjeeva Kumari Chinta, and B Triveni, "Evaluation of Rare Types of Breast Cancer among Indian Patients–a Retrospective Study from a Regional Cancer Center." Indian Journal of Surgical Oncology, Vol. 12pp. 286-89, (2021).
35- N. Hashemzadeh et al., "Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells." (in English), Nanomedicine, Article Vol. 16 (No. 24), pp. 2137-54, (2021).
36- A. Aghanejad et al., "A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors." (in English), International Journal of Biological Macromolecules, Review Vol. 207pp. 592-610, (2022).
37- Typically Benign Calcifications, "Mammographic Analysis of Breast Calcifications." Breast Imaging, E-Book: The Core Requisites, p. 36, (2022).
38- Luigi Rossi et al., "Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy." Cancer Chemotherapy and Pharmacology, Vol. 85pp. 105-11, (2020).
39- A. Aghanejad, A. R. Jalilian, S. Maus, H. Yousefnia, P. Geramifar, and D. Beiki, "Optimized production and quality control of 68Ga-DOTATATE." (in English), Iranian Journal of Nuclear Medicine, Article Vol. 24 (No. 1), pp. 29-36, (2016).
40- A. Aghanejad, A. R. Jalilian, Y. Fazaeli, D. Beiki, B. Fateh, and A. Khalaj, "Radiosynthesis and biodistribution studies of [62Zn/ 62Cu]-plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging." (in English), Journal of Radioanalytical and Nuclear Chemistry, Article Vol. 299 (No. 3), pp. 1635-44, (2014).
41- A. Tarighatnia et al., "Mucin-16 targeted mesoporous nano-system for evaluation of cervical cancerviadual-modal computed tomography and ultrasonography." (in English), New Journal of Chemistry, Article Vol. 45 (No. 40), pp. 18871-80, (2021).
42- M. Saberian, H. Hamzeiy, A. Aghanejad, and D. Asgari, "Aptamer-based nanosensors: Juglone as an attached-redox molecule for detection of small molecules." (in English), BioImpacts, Article Vol. 1 (No. 1), pp. 31-36, (2011).
43- S. Mohaghegh, A. Tarighatnia, Y. Omidi, J. Barar, A. Aghanejad, and K. Adibkia, "Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer." (in English), Journal of Microencapsulation, Article Vol. 39 (No. 4), pp. 394-408, (2022).
44- A. Tarighatnia et al., "Engineering and quantification of bismuth nanoparticles as targeted contrast agent for computed tomography imaging in cellular and animal models." (in English), Journal of Drug Delivery Science and Technology, Article Vol. 66(2021), Art no. 102895.
45- F. Vahidian et al., "siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468)." (in English), Molecular Biology Reports, Article Vol. 47 (No. 12), pp. 9541-51, (2020).
46- A. Mirzaei et al., "Preparation and Evaluation of 68Ga-ECC as a PET Renal Imaging Agent." (in English), Nuclear Medicine and Molecular Imaging, Article Vol. 49 (No. 3), pp. 208-16, (2015).
47- S. Rezaei, E. Gharapapagh, S. Dabiri, P. Heidari, and A. Aghanejad, "Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges." (in English), Life Sciences, Review Vol. 329(2023), Art no. 121970.
48- K. Kheyrolahzadeh, M. R. Tohidkia, A. Tarighatnia, P. Shahabi, N. D. Nader, and A. Aghanejad, "Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors." (in English), Life Sciences, Review Vol. 328(2023), Art no. 121917.
49- N. Vahidfar, A. Aghanejad, H. Ahmadzadehfar, S. Farzanehfar, and E. Eppard, "Theranostic advances in breast cancer in nuclear medicine." (in English), International Journal of Molecular Sciences, Review Vol. 22 (No. 9), (2021), Art no. 4597.
50- J. Kadkhoda, M. Akrami-Hasan-Kohal, M. R. Tohidkia, S. Khaledi, S. Davaran, and A. Aghanejad, "Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends." (in English), International Journal of Biological Macromolecules, Review Vol. 185pp. 664-78, (2021).
51- Javad Biabani Ardakani et al., "Molecular imaging of HER2 expression in breast cancer patients using the [99mTc] Tc-labeled small peptide." Clinical Breast Cancer, Vol. 23 (No. 2), pp. 219-30, (2023).
52- Rong Zhou et al., "18F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 131-36, (2023).
53- Jaehoon Shin et al., "Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma." Journal of Nuclear Medicine, Vol. 64 (No. 1), pp. 137-44, (2023).
54- Nasim Vahidfar, Ayuob Aghanejad, Hojjat Ahmadzadehfar, Saeed Farzanehfar, and Elisabeth Eppard, "Theranostic Advances in Breast Cancer in Nuclear Medicine." International Journal of Molecular Sciences. Vol. 22 (No. 9). DOI: 10.3390/ijms22094597
55- D. Asgari, A. Aghanejad, and J. S. Mojarrad, "An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate." (in English), Bulletin of the Korean Chemical Society, Article Vol. 32 (No. 3), pp. 909-14, (2011).
56- L. Barghi, A. Aghanejad, H. Valizadeh, J. Barar, and D. Asgari, "Modified Synthesis of Erlotinib Hydrochloride." (in English), Advanced Pharmaceutical Bulletin, Article Vol. 2 (No. 1), pp. 119-22, (2012).
57- Catherine Van Poznak et al., "Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline." Journal of clinical oncology, Vol. 33 (No. 24), p. 2695, (2015).
58- SM Kurian et al., "Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling." American Journal of Transplantation, Vol. 14 (No. 5), pp. 1164-72, (2014).
59- Emran Askari, Sara Harsini, Nasim Vahidfar, Ghasemali Divband, and Ramin Sadeghi, "177Lu-EDTMP for metastatic bone pain palliation: A systematic review and meta-analysis." Cancer biotherapy & radiopharmaceuticals, Vol. 36 (No. 5), pp. 383-90, (2021).
60- Naoki Niikura et al., "Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry." Annals of oncology, Vol. 27 (No. 3), pp. 480-87, (2016).
61- Naoki Niikura et al., "Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors." Journal of clinical oncology, Vol. 30 (No. 6), p. 593, (2012).
62- Thomas Decker et al., "Clonal evolution in patients with hormone receptor positive, HER-2 negative breast cancer treated with chemotherapy or CDK4/6 inhibitors." Oncology Research and Treatment, Vol. 45 (No. 5), pp. 248-53, (2022).
63- Ibiayi Dagogo-Jack and Alice T Shaw, "Tumour heterogeneity and resistance to cancer therapies." Nature reviews Clinical oncology, Vol. 15 (No. 2), pp. 81-94, (2018).
64- N. Vahidfar et al., "Development of radiolanthanide labeled porphyrin complexes as possible therapeutic agents in beast carcinoma xenografts." (in English), Radiochimica Acta, Article Vol. 102 (No. 7), pp. 659-68, (2014).
65- P. N. Nabi, N. Vahidfar, M. R. Tohidkia, A. A. Hamidi, Y. Omidi, and A. Aghanejad, "Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer." (in English), International Journal of Biological Macromolecules, Article Vol. 174pp. 185-97, (2021).
66- A. Tarighatnia, M. R. Fouladi, N. D. Nader, A. Aghanejad, and H. Ghadiri, "Recent trends of contrast agents in ultrasound imaging: a review of the classifications and applications." (in English), Materials Advances, Review (2022).
67- Tjeerd S Aukema et al., "The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques." European Journal of Surgical Oncology (EJSO), Vol. 36 (No. 4), pp. 387-92, (2010).
68- Oreste Bagni, Luca Filippi, and Orazio Schillaci, "The role of 18F-FDG positron emission tomography in the follow-up of liver tumors treated with 90Yttrium radioembolization." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 5 (No. 3), p. 220, (2015).
69- Maria Rinzivillo et al., "Clinical usefulness of 18F‐fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero‐pancreatic neuroendocrine neoplasms." The Oncologist, Vol. 23 (No. 2), pp. 186-92, (2018).
70- Jens Sörensen et al., "Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT." Theranostics, Vol. 6 (No. 2), p. 262, (2016).
71- Irina Velikyan et al., "Diagnostic HER2-binding radiopharmaceutical,[68Ga] Ga-ABY-025, for routine clinical use in breast cancer patients." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 9 (No. 1), p. 12, (2019).
72- Gustavo A Viani, Sergio L Afonso, Eduardo J Stefano, Ligia I De Fendi, and Francisco V Soares, "Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials." BMC cancer, Vol. 7 (No. 1), pp. 1-11, (2007).
73- Eva Karlsson et al., "Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events." European journal of cancer, Vol. 50 (No. 3), pp. 517-24, (2014).
74- J Zidan, I Dashkovsky, C Stayerman, W Basher, C Cozacov, and A Hadary, "Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease." British journal of cancer, Vol. 93 (No. 5), pp. 552-56, (2005).
75- Frederike Bensch et al., "89 Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45pp. 2300-06, (2018).
76- Kenji Tamura et al., "64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer." Journal of Nuclear Medicine, Vol. 54 (No. 11), pp. 1869-75, (2013).
77- Seyed Pezhman Shirmardi et al., "Preparation and biodistribution study of a 99mTc-labeled toxic fraction of Iranian mesobuthus eupeus scorpion venom." (2010).
78- Paolo Rainone et al., "Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer." International journal of nanomedicine, pp. 3447-61, (2017).
79- Jens Sörensen et al., "First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule." Journal of Nuclear Medicine, Vol. 55 (No. 5), pp. 730-35, (2014).
80- Frank Alexis, Eric Pridgen, Linda K Molnar, and Omid C Farokhzad, "Factors affecting the clearance and biodistribution of polymeric nanoparticles." Molecular pharmaceutics, Vol. 5 (No. 4), pp. 505-15, (2008).
81- S. Khajeh, M. R. Tohidkia, A. Aghanejad, T. Mehdipour, F. Fathi, and Y. Omidi, "Phage display selection of fully human antibody fragments to inhibit growth-promoting effects of glycine-extended gastrin 17 on human colorectal cancer cells." (in English), Artificial Cells, Nanomedicine and Biotechnology, Article Vol. 46 (No. sup2), pp. 1082-90, (2018).
82- Hui Ma and Richard O’Kennedy, "The structure of natural and recombinant antibodies." Peptide Antibodies: Methods and Protocols, pp. 7-11, (2015).
83- Robyn L Stanfield and Ian A Wilson, "Antibody structure." Antibodies for Infectious Diseases, pp. 49-62, (2015).
84- Hennie R Hoogenboom, Andrew D Griffiths, Kevin S Johnson, David J Chiswell, Peter Hudson, and Greg Winter, "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains." Nucleic acids research, Vol. 19 (No. 15), pp. 4133-37, (1991).
85- Mark L Chiu, Dennis R Goulet, Alexey Teplyakov, and Gary L Gilliland, "Antibody structure and function: the basis for engineering therapeutics." Antibodies, Vol. 8 (No. 4), p. 55, (2019).
86- Karen Lam, Conrad Chan, and Raymond M Reilly, "Development and preclinical studies of 64Cu-NOTA-pertuzumab F (ab′) 2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT." in MAbs, (2017), Vol. 9 (No. 1): Taylor & Francis, pp. 154-64.
87- Peter M Smith-Jones, David B Solit, Timothy Akhurst, Farzana Afroze, Neal Rosen, and Steven M Larson, "Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors." Nature biotechnology, Vol. 22 (No. 6), pp. 701-06, (2004).
88- Ying Tang et al., "Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments." Nuclear medicine and biology, Vol. 32 (No. 1), pp. 51-58, (2005).
89- Ying Tang, Deborah Scollard, Paul Chen, Judy Wang, Claire Holloway, and Raymond M Reilly, "Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments." Nuclear medicine communications, Vol. 26 (No. 5), pp. 427-32, (2005).
90- Thijs H Oude Munnink et al., "Lapatinib and 17AAG reduce 89Zr-trastuzumab-F (ab′) 2 uptake in SKBR3 tumor xenografts." Molecular pharmaceutics, Vol. 9 (No. 11), pp. 2995-3002, (2012).
91- Claudia T Mendler, Torben Gehring, Hans-Jürgen Wester, Markus Schwaiger, and Arne Skerra, "89Zr-labeled versus 124I-labeled αHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo." Journal of Nuclear Medicine, Vol. 56 (No. 7), pp. 1112-18, (2015).
92- Volkan Beylergil et al., "Pilot study of 68Ga-DOTA-F (ab′) 2-trastuzumab in patients with breast cancer." Nuclear medicine communications, Vol. 34 (No. 12), p. 1157, (2013).
93- Gregory P Adams et al., "Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erb B-2 single-chain Fv." Cancer Research, Vol. 53 (No. 17), pp. 4026-34, (1993).
94- GP Adams et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu." British journal of cancer, Vol. 77 (No. 9), pp. 1405-12, (1998).
95- Irina V Balalaeva, Tatiana A Zdobnova, Irina V Krutova, Anna A Brilkina, Ekaterina N Lebedenko, and Sergey M Deyev, "Passive and active targeting of quantum dots for whole‐body fluorescence imaging of breast cancer xenografts." Journal of Biophotonics, Vol. 5 (No. 11‐12), pp. 860-67, (2012).
96- Mikaela Friedman and Stefan Ståhl, "Engineered affinity proteins for tumour‐targeting applications." Biotechnology and applied biochemistry, Vol. 53 (No. 1), pp. 1-29, (2009).
97- Nasim Vahidfar, Saeed Farzanefar, Hojjat Ahmadzadehfar, Eóin N Molloy, and Elisabeth Eppard, "A review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies." Cancers, Vol. 14 (No. 7), p. 1779, (2022).
98- Mohamed Altai et al., "Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA." Nuclear medicine and biology, Vol. 39 (No. 4), pp. 518-29, (2012).
99- Torun Engfeldt et al., "Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99m Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34pp. 722-33, (2007).
100- Anna Orlova et al., "Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors." Cancer Research, Vol. 67 (No. 5), pp. 2178-86, (2007).
101- Vladimir Tolmachev et al., "111In-benzyl-DTPA–ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors." Journal of Nuclear Medicine, Vol. 47 (No. 5), pp. 846-53, (2006).
102- Richard P Baum et al., "Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules." Journal of Nuclear Medicine, Vol. 51 (No. 6), pp. 892-97, (2010).
103- Mattias Sandström et al., "Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients." Journal of Nuclear Medicine, Vol. 57 (No. 6), pp. 867-71, (2016).
104- Jiong Cai et al., "Non-invasive monitoring of HER2 expression in breast cancer patients with 99mTc-Affibody SPECT/CT." Iranian Journal of Radiology, Vol. 17 (No. 1), (2020).
105- Shushan Ge et al., "radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides." Molecules, Vol. 26 (No. 21), p. 6482, (2021).
106- Ruisi Fu, Laurence Carroll, Gokhan Yahioglu, Eric O Aboagye, and Philip W Miller, "Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications." ChemMedChem, Vol. 13 (No. 23), pp. 2466-78, (2018).
107- Vladimir Tolmachev and Anna Orlova, "Affibody molecules as targeting vectors for PET imaging." Cancers, Vol. 12 (No. 3), p. 651, (2020).
108- Joachim Feldwisch and Vladimir Tolmachev, "Engineering of affibody molecules for therapy and diagnostics." Therapeutic Proteins: Methods and Protocols, pp. 103-26, (2012).
109- Andrew S Greenberg, David Avila, Marianne Hughes, Austin Hughes, E Churchill McKinney, and Martin F Flajnik, "A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks." nature, Vol. 374 (No. 6518), pp. 168-73, (1995).
110- CTSG Hamers-Casterman et al., "Naturally occurring antibodies devoid of light chains." nature, Vol. 363 (No. 6428), pp. 446-48, (1993).
111- Philipp Holliger and Peter J Hudson, "Engineered antibody fragments and the rise of single domains." Nature biotechnology, Vol. 23 (No. 9), pp. 1126-36, (2005).
112- Thomas Hermans, Frédéric Nguyen, Maria Klepikova, Alain Dassargues, and Jef Caers, "Uncertainty quantification of medium‐term heat storage from short‐term geophysical experiments using Bayesian evidential learning." Water Resources Research, Vol. 54 (No. 4), pp. 2931-48, (2018).
113- Padmapriyadarsini Chandrasekaran, Natarajan Saravanan, Ramalingam Bethunaickan, and Srikanth Tripathy, "Malnutrition: modulator of immune responses in tuberculosis." Frontiers in immunology, Vol. 8p. 1316, (2017).
114- Catarina Xavier et al., "18F-nanobody for PET imaging of HER2 overexpressing tumors." Nuclear medicine and biology, Vol. 43 (No. 4), pp. 247-52, (2016).
115- Marleen Keyaerts et al., "Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma." Journal of Nuclear Medicine, Vol. 57 (No. 1), pp. 27-33, (2016).
116- Marleen Keyaerts et al., "Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients." Annals of oncology, Vol. 30pp. iii25-iii26, (2019).
117- Betül Altunay et al., "99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50 (No. 4), pp. 1005-13, (2023).
118- Renske Altena et al., "Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications." EJNMMI research, Vol. 13 (No. 1), p. 43, (2023).
119- Tessa De Pauw et al., "Current status and future expectations of nanobodies in oncology trials." Expert Opinion on Investigational Drugs, pp. 1-17, (2023).
| Files | ||
| Issue | Vol 11 No 4 (2024) | |
| Section | Literature (Narrative) Review(s) | |
| DOI | https://doi.org/10.18502/fbt.v11i4.16517 | |
| Keywords | ||
| Breast Cancer Antibody-Based Imaging Radiolabel Molecular Imaging Nanobody | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Gerami R, Altafi M, Shahpar Z, Izadpanah E, Soltani S, Naderloo O, Tarighatnia A. Recent Advances and Future Perspectives in Radiolabeled Antibody Fragments for Breast Cancer Molecular Imaging. Frontiers Biomed Technol. 2023;11(4):677-691.
